Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
125 participants
OBSERVATIONAL
2014-10-31
2017-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Changes in the patterns of health care delivery have shifted the care of the elderly from acute care settings to the community and long-term care facilities. As the European population ages, more and more people will become nursing home residents, many of whom will have a suspicion of, or be diagnosed with, and eventually die from, cancer. Although cancer is very common in elderly nursing home residents, it is poorly studied. This lack of information may impact on clinical decision making and the appropriateness of treatments offered and therefore collection of this information is needed.
This project has two main objectives. The first objective is to report on demographics, referral patterns and motives for non-referral, anti-cancer treatments and outcome of patients in nursing homes with suspected or diagnosed active invasive cancer where a diagnostic or treatment decision has to be taken. The second objective is to develop better prognostic tools (for survival) including biological markers of ageing to help treatment decisions in the elderly.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Screening Tools to Predict Treatment Outcome in Older Cancer Patients Who Are Undergoing Treatment
NCT01005693
Evaluating Quality and Cost of (Partial) Oncological Home-Hospitalization
NCT03668275
Study of Physical and Mental Health of Older Patients With Newly Diagnosed Cancer
NCT00769951
Optimization and Improvement of Care Course for 75 Years and Over Patient With Cancer and Living in Nursing Home on the Marseille Agglomeration
NCT03103659
A Clinical Trial to Evaluate the Sensitivity of a Number of Clinical and Psychological Outcome Measures for Cancer Patients Being Treated at the Hospital Day Care Unit or (Partially) at Home
NCT03073499
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control cohort
Nursing home residents without cancer
No interventions assigned to this group
Cancer patient cohort
Patients in nursing homes with suspected or diagnosed active invasive cancer where a diagnostic or treatment decision has to be taken
No interventions assigned to this group
Biomarker cohort
Subgroup of individuals in the control cohort willing to provide a blood sample
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age ≥ 65 years
* Residents in a nursing home in the Armonea network in Belgium.
* Absence of any psychological, familial, or sociological condition potentially hampering compliance with the study protocol; those conditions should be discussed with the patient/proxy before registration in the study.
* Written informed consent must be given according to ICH/GCP, and national/local regulations.
* The treating general practitioner (GP) is willing to provide medical information required by the study.
Cancer patient cohort:
Patients must have a new cancer event defined as one of:
* A strong clinical suspicion (based on physician's judgement) of a new cancer where a diagnostic or therapeutic decision needs to be taken.
* A strong clinical suspicion (based on physician's judgement) of progression of a previously known cancer where a diagnostic or therapeutic decision needs to be taken.
* Diagnosis of a new cancer where a diagnostic or therapeutic decision needs to be taken.
* Diagnosis of progression of a previously known cancer where a diagnostic or therapeutic decision needs to be taken.
All invasive cancer types and all histologies are eligible. All lines of treatment are eligible. Patients who are diagnosed with cancer during routine medical examinations for some other medical condition
Control cohort:
• Absence of known active invasive cancer, or strong clinical suspicion of cancer (based on physician's judgement) at baseline.
Exclusion Criteria
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Armonea
UNKNOWN
European Organisation for Research and Treatment of Cancer - EORTC
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hans Wildiers
Role: STUDY_CHAIR
UZ Leuven, Belgium
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Armonea nursing homes network
Mechelen, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EORTC-1221
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.